pharmaphorum

MAY 10, 2022

Results of the pilot in 45 patients with non-small cell lung cancer (NSCLC) treated with Tecentriq with and without chemotherapy were published in 2020. The data showed that patients as well as physicians and nursing staff found the digital tool allowed “more efficient and focused communication” as well as time savings.

Chemotherapy 137

Chemotherapy Communication 137

European Pharmaceutical Review

NOVEMBER 6, 2023

In addition to being indicated in those with progressive disease, Mirati Therapeutics shared that the treatment is also authorised for patients with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy. Adagrasib is available for eligible NSCLC patients as a 200mg oral tablet.

Chemotherapy 98

Chemotherapy Hospitals 98

Big Molecule Watch

MAY 22, 2023

According to the press release, FYLNETRA—Amneal’s third biosimilar launch in the United States since late last year—is used to treat neutropenia (low neutrophils, a type of white blood cell that fights infection) which is commonly experienced by patients undergoing chemotherapy.

Biosimilars 72

Biosimilars Chemotherapy 72

pharmaphorum

JULY 20, 2022

The study compared VB-111 plus paclitaxel chemotherapy to paclitaxel given on its own, but showed no significant difference between the two groups, with PFS and OS in both coming in at just over five months and 13 months, respectively.

Chemotherapy 98

Chemotherapy Immunization Immunity 98

pharmaphorum

JUNE 11, 2021

Now, results from the ongoing TRANSFORM study show that Breyanzi was more effective than the standard second-line treatment – salvage therapy followed by high-dose chemotherapy and a stem cell transplant – at fending off disease recurrence.

Chemotherapy 83

Chemotherapy Labelling 83

pharmaphorum

OCTOBER 6, 2022

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.

Generic Medicine 98

Generic Medicine Chemotherapy 98

pharmaphorum

JANUARY 18, 2021

J&J’s Janssen pharma unit got approval for Darzalex Faspro as a multiple myeloma treatment in the US last May and in Europe the following month, lending further momentum to a franchise that looks set to make more than $4 billion in sales in calendar 2020. It has already been submitted for approval in the EU.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JULY 16, 2021

The UK cost-effectiveness body first turned down Zytiga (abiraterone acetate) for this use in June 2020, but said four months later that it would reconsider its decision. That review has now concluded, and NICE has said it won’t change its mind.

Chemotherapy 52

Chemotherapy Drug Pricing 52

pharmaphorum

OCTOBER 4, 2022

AZ and Merck’s drug was also approved as a second-line therapy after Xtandi or Pfizer’s Zytiga (abiraterone) for mCRPC in 2020, but only as a monotherapy in patients with tumours that express homologous recombination repair (HRR) gene mutation – including BRCA1/2 and ATM).

Chemotherapy 52

Chemotherapy Labelling 52

pharmaphorum

DECEMBER 14, 2021

The results come on the tail of new second-line results with Yescarta and another CD19-targeting CAR-T, Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel), which sought to answer the question of whether they could be an alternative to chemotherapy and a stem cell transplant – the go-to therapy for relapsed LBCL patients.

Chemotherapy 98

Chemotherapy Labelling 98

European Pharmaceutical Review

AUGUST 10, 2022

In the study ( NCT04752059 , EudraCT 2020-000981-41 ), the Austrian research team led by Matthias Preusser and Rupert Bartsch, both from the Division of Oncology, investigated the agent T-Dxd as a possible new therapeutic approach in cases where breast cancer spreads to the brain. .”

Chemotherapy 98

Chemotherapy Labelling Hospitals 98

pharmaphorum

DECEMBER 9, 2022

AZ estimates that approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative and, if first-line endocrine therapies fail, their only option currently is single-agent chemotherapy.

Chemotherapy 98

Chemotherapy Drug Development 98

RX Note

MARCH 31, 2025

Patients on chemotherapy, oral corticosteroids or drugs for HIV May be susceptible to more severe infection. 2019 Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis, 2020 Cold sores located in the mouth or close to the eye Outside scope of community pharmacy.

Community Pharmacies 52

Community Pharmacies Chemotherapy 52

pharmaphorum

NOVEMBER 26, 2020

Y-mAbs said last month it is expecting to resubmit omburtamab for approval to the FDA in late 2020 or early 2021, and will also start clinical trials of a next-generation version of the drug before year-end in neuroblastoma as well as B7-H3-positive leptomeningeal tumours. And combination trials with chemotherapy are also planned.

Chemotherapy 105

Chemotherapy Labelling 105

Pharmaceutical Business Review

OCTOBER 23, 2024

MARGENZA, a HER2/neu receptor antagonist, received FDA approval in December 2020. It is used in combination with chemotherapy for adult patients with metastatic HER2-positive breast cancer who have previously undergone two or more anti-HER2 regimens.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

APRIL 27, 2021

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively. The post FDA looks at pulling speedy approvals for three cancer drugs appeared first on.

Chemotherapy 90

Chemotherapy Documentation Drug Development 90

pharmaphorum

JANUARY 11, 2022

The DTx, called BNT200, is described as a first-of-its-kind DTx to treat anxiety and depression in adults with acute myeloid leukaemia (AML) who are hospitalised for a regimen of high-intensity induction chemotherapy. The DTx is an on-demand stress management intervention with content synchronised with high-intensity chemotherapy treatment.

Chemotherapy 64

Chemotherapy Hospitals 64

pharmaphorum

JANUARY 26, 2021

The European Commission has cleared Bavencio (avelumab) for locally advanced or metastatic urothelial carcinoma (UC) – the most common form of bladder cancer – in cases where cancer hasn’t progressed after platinum-containing chemotherapy. The green light in Europe comes six months after the FDA backed the same use for the drug in the US.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

NOVEMBER 16, 2020

Phesgo has been recommended by the CHMP for use in combination with chemotherapy in early HER2-positive breast cancer – pre- and post-surgery – as well as for front-line therapy of HER2-positive breast cancer that has already spread in the body. A CHMP recommendation is usually followed by EMA approval within a few weeks. billion ($3.2

Biosimilars 98

Biosimilars Chemotherapy 98

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology.

Drug Development 132

Drug Development Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

pharmaphorum

MAY 26, 2022

The US regulator has approved Tibsovo (ivosidenib) in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) as a first-line therapy for IDH1-mutated acute myeloid leukaemia (AML), expanding the eligible patient population for the drug. for the Tibsovo arm and 14.9% for the control group.

Chemotherapy 52

Chemotherapy Labelling 52

pharmaphorum

JANUARY 20, 2021

billion in revenues in the first nine months of 2020 – as well as Rigel Pharma/Grifols’ recently-approved oral drug Tavalisse/Tavlesse (fostamatinib) and Amgen’s injectable Nplate (romiplostim) in the ITP indication. Sobi’s drug will have to compete with various drugs including Novartis’ Promacta (eltrombopag) – which made $1.2

Chemotherapy 52

Chemotherapy Immunization Immunity 52

Pharmaceutical Technology

JUNE 28, 2022

The treatment is intended for breast cancer patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative who have previously received neoadjuvant or adjuvant chemotherapy. A PARP inhibitor, Lynparza is co-developed and co-marketed by Merck and AstraZeneca.

Research Laboratories 64

Research Laboratories Chemotherapy 64

pharmaphorum

JANUARY 25, 2023

9,273,135 and 9,320,811, which cover the use of a CTLA4 inhibitor in combination with a PD-1 inhibitor and chemotherapy drug gemcitabine, respectively. Growth for the drug has picked up in the last couple of years, including approval in 2020 as a low-dose add-on to Opdivo in various liver and lung cancer settings. 1:23-cv-00079).

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. 2020; 19(10): 2044–56. These patients face a poorer prognosis and shorter survival rates compared with lung cancer driven by more common EGFR mutations. Cancer Ther.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

JULY 19, 2022

China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy, partnered with US biotech G1 Therapeutics. Simcere said that the number of new cancer patients requiring chemotherapy in China is expected to reach 4.2

Chemotherapy 59

Chemotherapy 59

European Pharmaceutical Review

DECEMBER 6, 2022

In July 2021, the French temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme was the subject of a major reform, initially published within the 2021 healthcare plan on the 14th December 2020 (Article 78 – La Loi de financement de la sécurité sociale , FSSL). References. Available from: [link].

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JULY 15, 2021

Data from the study was published in the New England Journal of Medicine in May 2020, and won tepotinib a breakthrough designation from the FDA. The MHRA said that the standard treatment of non-small cell lung cancer is chemotherapy or immunotherapy with checkpoint inhibitors if there is no targeted therapy available.

Chemotherapy 81

Chemotherapy 81

pharmaphorum

FEBRUARY 17, 2021

At an interim analysis, Lynparza (olaparib) reduced recurrence of disease compared to placebo in women with BRCA-mutated, HER2-negative breast cancer after surgery and chemotherapy to remove the tumour. million women were diagnosed with breast cancer worldwide in 2020, and BRCA mutations are found in approximately 5% of them.

Chemotherapy 59

Chemotherapy 59

Pharmaceutical Technology

SEPTEMBER 13, 2022

In 2020, Keytruda was approved for previously untreated metastatic MSI-H/dMMR CRC, with the KEYNOTE-177 study demonstrating an 8.3-month month progression-free survival (PFS) benefit over SOC chemotherapy. MSI-H/dMMR CRC accounts for 10-15% of all CRC.

Immunization 69

Immunization Immunity Chemotherapy 69

Pharmaceutical Technology

JUNE 27, 2022

The transaction is focused on Epizyme’s lead asset, Tazverik (tazemetostat), a chemotherapy-free EZH2 a inhibitor. In 2020, the US Food and Drug Administration (FDA) granted accelerated approval for the drug. The company will begin an all-cash tender offer through its subsidiary to buy Epizyme’s all outstanding shares for $1.45

Chemotherapy 59

Chemotherapy Compounding 59

Pharmaceutical Technology

AUGUST 16, 2022

This was followed by a further deal for the global development and commercialisation of another ADC, datopotamab deruxtecan (DS-1062) in 2020, with a deal value of up to $6bn. months compared with patients treated with standard-of-care chemotherapy.

Chemotherapy 59

Chemotherapy Immunization Immunity 59

Pharmaceutical Technology

SEPTEMBER 26, 2022

Since 2020, palbociclib has been offered through the Cancer Drugs Fund (CDF), while additional data was obtained to address doubts on the drug’s cost efficiency and to what extent it prolongs the life expectancy of people.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours.

Immunization 84

Immunization Immunity Chemotherapy Medical Schools 84

pharmaphorum

OCTOBER 11, 2022

The Scottish Medicines Consortium (SMC) gave the go-ahead to the regimen based on data from the KEYNOTE-775 study , which showed that the duo can increase survival time for patients and may improve quality of life by reducing the symptom burden compared to standard chemotherapy.

Chemotherapy 52

Chemotherapy Documentation 52

pharmaphorum

MARCH 14, 2022

.” One of Blue Note’s DTx products – used to treat anxiety and depression in adults with acute myeloid leukaemia (AML) who are hospitalised for a regimen of high-intensity induction chemotherapy – was awarded a breakthrough designation by the FDA earlier this year.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

NOVEMBER 10, 2020

Previously treated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVie’s Venclyxto and Roche’s Gazyva. The decision by NICE allows for the 12-month fixed duration treatment option based on data from the phase 3 CLL14 trial.

Chemotherapy 52

Chemotherapy Hospitals 52